This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Monday is lipoprotein(a) awareness day. ABC News chief medical correspondent Dr. Tara Narula shares what you need to know.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

High Lipoprotein (a) is a genetic condition that increases the risk of early heart attacks and strokes. It is one of the most common genetic risk factors for cardiovascular disease, yet it remains ...

Opens in a new tab or window CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...